PARIS (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) plans to build up its presence in biotechnology, particularly in manufacturing capacity, its head of research said on Monday."We will reinforce in biotech -- it’s part of our weakness,” Marc Cluzel told reporters ahead of a research and development presentation. “In terms of manufacturing, we will try and do it by acquisitions.”
